iBio (IBIO) Acquisitions (2022)
iBio's (IBIO) quarterly Acquisitions came in at $692000.0 in Q3 2022.
iBio (IBIO) Acquisitions (2022) Analysis & Trends
iBio (IBIO) has 1 years of Acquisitions data on file, last reported at $692000.0 in Q3 2022.
- On a quarterly basis, Acquisitions changed N/A year-over-year to $692000.0 in Q3 2022; TTM through Jun 2023 was $692000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $692000.0, changed N/A from the prior year.
- Acquisitions for Q3 2022 stood at $692000.0.
- Over the last five years, Acquisitions for IBIO reached as high as $692000.0 in Q3 2022 and fell as low as $692000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | - |
| 10 | iBio | 167.44 Mn | 167.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 692,000.00 |